CADEAP

Ceres and District Environment and Amenity Protection Group

Much the same way that humans concentrate their eyes.

In a single set of findings, experts had demonstrated that the nasal area can become a gas chromatograph , absorbing substances for different times depending on how easily they connect to the water-based mucus on the sensory receptors in the nasal area. Odorants which have high ‘sorption values’ are easily absorbed into the mucus, while odors that usually do not absorb easily into drinking water have lower sorption ideals.Scott Salka, Chief Executive Officer of Ambit Biosciences. ‘The Phase I medical data we’ve noticed for AC220 in AML are really encouraging and supports the further advancement of the highly selective second-era FLT3 inhibitor.’ Related StoriesPenn research forms basis for fresh treatment techniques for Sezary syndromePotential brand-new drug target for acute myeloid leukemiaDr. Paul Liu called 2015 Distinguished Alumnus for contributions to leukemia researchData Highlights for AC220 consist of: ORAL PRESENTATIONS Abstract #636 AC220, a Potent, Selective, Second Era FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Stage 1 AML Study Shown by: Jorge Cortes, MD Program Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Time: Monday, December 7, 2009, 5:45pm , Morial Convention Center Area 343-345 POSTER PRESENTATIONS Abstract# 2053 AC220 – A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Types of Acute Myeloid Leukemia and Provides Sustained Safety Following Chronic Administration Session Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Sunday, 6 December, 2009, 6:00 – 8:00pm, Hall E, Poster Board II-45 Abstract#: 2052 AC220, a Powerful and Specific FLT3 Inhibitor, Enhances the Cytotoxic Ramifications of Chemotherapeutic Agents in Cell Lifestyle and in Mouse Tumor Xenograft Program Name: Acute Myeloid Leukemia – Therapy, excluding Transplantation II Sunday, December 6, 2009, 6:00 PM – 8:00 PM, Hall E, Poster Board II-44..